Chit Chat
There is currently 1 person viewing this thread.
The Oxford University vaccine, tipped as a “front runner” in the race to develop a coronavirus jab, does not stop the virus in monkeys and may only be partially effective, experts have warned.
A trial of the vaccine in rhesus macaque monkeys did not stop the animals from catching the virus and has raised questions about the vaccine’s likely human efficacy and ongoing development.
The vaccine, known as ChAdOx1 nCoV-19, is now undergoing human trials in Britain. The Government has brokered a deal between Oxford University and AstraZeneca, the drug company, to produce up to 30 million doses if it proves successful having ploughed £47m into the research.
“All of the vaccinated monkeys treated with the Oxford vaccine became infected when challenged as judged by recovery of virus genomic RNA from nasal secretions,” said Dr William Haseltine, a former Harvard Medical School professor who had a pivotal role in the development of early HIV/Aids treatments.
“There was no difference in the amount of viral RNA detected from this site in the vaccinated monkeys as compared to the unvaccinated animals. Which is to say, all vaccinated animals were infected,” he wrote in an article on Forbes.
Jonathan Ball, professor of molecular virology at the University of Nottingham, said that the vaccine data suggests that the jab may not be able to prevent the spread of the virus between infected individuals.
“That viral loads in the noses of vaccinated and unvaccinated animals were identical is very significant. If the same happened in humans, vaccination would not stop spread,” he said.
“I genuinely believe that this finding should warrant an urgent re-appraisal of the ongoing human trials of the ChAdOx1 vaccine.”
The trials investigated the immune response to the Oxford vaccine in rhesus macaque monkeys and were carried out at the National Institute of Health’s Rocky Mountain Laboratory in the US, with initial results published in a press release at the end of April.
The results were said at the time to be encouraging. But publication of the full trial results last week shows the vaccine did not prevent the animals catching the virus, although there was evidence it may reduce the severity of the disease.
This is in contrast to a Chinese vaccine trial in April that did appear to stop the development of Covid-19 in monkeys. That trial, by Sinovac Biotech, a privately held Beijing-based company, used a modified version of the full Sars-Cov-2 virus in its vaccine, while the Oxford vaccine uses a common cold virus to try and provoke an immune response.
In the Oxford monkey trial, six monkeys were infected with single doses of ChAdOx1 nCoV-19 and exposed to the coronavirus. A control group of three non-vaccinated monkeys were also infected. Both the immunised and non-immunised monkeys were then monitored for seven days for signs of developing Covid-19.
One measure of infection is an increased breathing rate as the virus attacks the lungs - three of the vaccinated animals displayed this symptom. On autopsy, the researchers found the virus in the vaccinated monkey’s lungs.
On the up side, none of the vaccinated monkeys displayed pneumonia - which suggests that while not stopping the virus, it may be partially protective.
Dr Haseltine said this was “encouraging”, but that “experience with other vaccines tells us that is not a firm guarantee that such will be the case for humans.”
“It is crystal clear that the vaccine did not provide sterilizing immunity to the virus challenge, the gold standard for any vaccine. It may provide partial protection,” he said.
The doubts about the vaccine come after Alok Sharma, the Business Secretary, said that the speed at which Oxford was pushing ahead with development was “genuinely unprecedented” and that the first clinical trials were “progressing well”.
He also announced £84 million of additional funding to further accelerate the vaccine research at Oxford University and another UK vaccine candidate being developed by Imperial College.
A trial of the vaccine in rhesus macaque monkeys did not stop the animals from catching the virus and has raised questions about the vaccine’s likely human efficacy and ongoing development.
The vaccine, known as ChAdOx1 nCoV-19, is now undergoing human trials in Britain. The Government has brokered a deal between Oxford University and AstraZeneca, the drug company, to produce up to 30 million doses if it proves successful having ploughed £47m into the research.
“All of the vaccinated monkeys treated with the Oxford vaccine became infected when challenged as judged by recovery of virus genomic RNA from nasal secretions,” said Dr William Haseltine, a former Harvard Medical School professor who had a pivotal role in the development of early HIV/Aids treatments.
“There was no difference in the amount of viral RNA detected from this site in the vaccinated monkeys as compared to the unvaccinated animals. Which is to say, all vaccinated animals were infected,” he wrote in an article on Forbes.
Jonathan Ball, professor of molecular virology at the University of Nottingham, said that the vaccine data suggests that the jab may not be able to prevent the spread of the virus between infected individuals.
“That viral loads in the noses of vaccinated and unvaccinated animals were identical is very significant. If the same happened in humans, vaccination would not stop spread,” he said.
“I genuinely believe that this finding should warrant an urgent re-appraisal of the ongoing human trials of the ChAdOx1 vaccine.”
The trials investigated the immune response to the Oxford vaccine in rhesus macaque monkeys and were carried out at the National Institute of Health’s Rocky Mountain Laboratory in the US, with initial results published in a press release at the end of April.
The results were said at the time to be encouraging. But publication of the full trial results last week shows the vaccine did not prevent the animals catching the virus, although there was evidence it may reduce the severity of the disease.
This is in contrast to a Chinese vaccine trial in April that did appear to stop the development of Covid-19 in monkeys. That trial, by Sinovac Biotech, a privately held Beijing-based company, used a modified version of the full Sars-Cov-2 virus in its vaccine, while the Oxford vaccine uses a common cold virus to try and provoke an immune response.
In the Oxford monkey trial, six monkeys were infected with single doses of ChAdOx1 nCoV-19 and exposed to the coronavirus. A control group of three non-vaccinated monkeys were also infected. Both the immunised and non-immunised monkeys were then monitored for seven days for signs of developing Covid-19.
One measure of infection is an increased breathing rate as the virus attacks the lungs - three of the vaccinated animals displayed this symptom. On autopsy, the researchers found the virus in the vaccinated monkey’s lungs.
On the up side, none of the vaccinated monkeys displayed pneumonia - which suggests that while not stopping the virus, it may be partially protective.
Dr Haseltine said this was “encouraging”, but that “experience with other vaccines tells us that is not a firm guarantee that such will be the case for humans.”
“It is crystal clear that the vaccine did not provide sterilizing immunity to the virus challenge, the gold standard for any vaccine. It may provide partial protection,” he said.
The doubts about the vaccine come after Alok Sharma, the Business Secretary, said that the speed at which Oxford was pushing ahead with development was “genuinely unprecedented” and that the first clinical trials were “progressing well”.
He also announced £84 million of additional funding to further accelerate the vaccine research at Oxford University and another UK vaccine candidate being developed by Imperial College.
sort by:
Show
per page
Replies: 7
|
By:
i'm so shocked Mr Blank; quite depressed in fact. I shall have to contact my friends in the pharmaceutical industry, & tell them that unfortunately they will have to make room on the shelf for yet another antiviral. Pharmacotherapy lives on though; so never fear
|
|
By:
 |
|
By:
I suppose this may have interrupted their quest for one for the flu ? Work in progress i suspect
|
|
By:
common cold comes first JW; priorites sir, priorities
|
|
By:
Modernas vaccine looks the one if Stephane Bancels reactions are of face value.
Share price up 25% on trial results. |
|
By:
Whoever finds it Uncle Bill wins he's funded the lot
|
|
By:
handjob ordering a 100 million was the giveaway
 |